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Abstract
A mouse-adapted strain of Ebola Zaire virus produces a fatal infection when BALB/cj mice are infected intraperitoneally (ip) but
subcutaneous (sc) infection with the same virus fails to produce illness and confers long-term protection from lethal ip rechallenge. To
identify immune correlates of protection in this model, we compared viral replication and cytokine/chemokine responses to Ebola virus in
mice infected ip (10 PFU/mouse), or sc (100 PFU/mouse) and sc “immune” mice rechallenged ip (106 PFU/mouse) at several time points
postinfection (pi). Ebola viral antigens were detected in the serum, liver, spleen, and kidneys of ip-infected mice by day 2 pi, increasing up
to day 6. Sc-infected mice and immune mice rechallenged ip had no detectable viral antigens until day 6 pi, when low levels of viral antigens
were detected in the livers of sc-infected mice only. TNF- and MCP-1 were detected earlier and at significantly higher levels in the serum
and tissues of ip-infected mice than in sc-infected or immune mice challenged ip. In contrast, high levels of IFN- and IFN- were found
in tissues within 2 days after challenge in sc-infected and immune mice but not in ip-infected mice. Mice became resistant to ip challenge
within 48 h of sc infection, coinciding with the rise in tissue IFN- levels. In this model of Ebola virus infection, the nonlethal sc route of
infection is associated with an attenuated inflammatory response and early production of antiviral cytokines, particularly IFN-, as compared
with lethal ip infection.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Ebola viruses are members of the family Filoviridae and
are the cause of a severe hemorrhagic fever in humans in
Africa. The virus reappears in infrequent epidemics that are
characterized by human-to-human transmission resulting in
a febrile illness often associated with hemorrhagic manifes-
tations in the skin and mucosal membranes. The first rec-
ognized epidemics of Ebola hemorrhagic fever (EHF) were
simultaneous outbreaks in Zaire and Sudan in 1976, in
which there were a total of 610 cases with a case fatality rate
of 90% (in the Congo) and 55% (in Sudan) (Anonymous,
1978a,b). Major outbreaks of EHF with large case numbers
and similar mortality rates have occurred subsequently in
1979 (Sudan), 1995 (Zaire), and 2000 (Uganda) (Anony-
mous, 2001; Baron et al., 1983; Khan et al., 1999). In each
of these outbreaks, the public health priorities associated
with this highly transmissible disease have understandably
mandated the institution of measures aimed primarily at
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containing the epidemic, with little opportunity for research
into the biology of the virus or to identify factors that
correlate with survival or protection against severe disease.
The small numbers of survivors and their location in remote
Central-East Africa have been a further obstacle to well-
designed studies of EHF.
In human infections, replication of virus in the primary
target cells (macrophages and endothelial cells) occurs early
in the disease, often during the asymptomatic phase (Feld-
mann et al., 1999; Schnittler and Feldmann, 1998; Zaki and
Goldsmith, 1999). Further organ dissemination of the virus
follows, accompanied by symptomatic illness with fever,
skin rashes, and mucosal hemorrhagic lesions (in more
severe disease). There is a prominent gastrointestinal com-
ponent to the illness, with abdominal pain, nausea, vomit-
ing, and diarrhea, often with melena. This phase is recog-
nized in the laboratory by the appearance of viral antigen in
the serum, titers of which rise rapidly as the illness
progresses. In surviving patients, the appearance of anti-
Ebola antibodies typically occurs in the second week of
illness followed by the disappearance of viral antigens from
circulation (Ksiazek et al., 1999a). The clearance of the
virus is likely to be mediated by antigen-specific cellular
responses (Baize et al., 1999; Gupta et al., 2001b; Sullivan
et al., 2000; Wilson and Hart, 2001). In fatal cases, how-
ever, the illness proceeds rapidly with a progressive rise in
circulating virus titers accompanied by shock and multior-
gan failure and hemorrhage from skin and mucosal sites
occurs in a substantial proportion of fatal cases.
Studies done during and after outbreaks have succeeded,
to some extent, in defining the virology and antibody re-
sponse kinetics of human Ebola virus infections (Ksiazek et
al., 1999a), but the absence of a sophisticated technical/
laboratory infrastructure in EHF- endemic areas has made it
impossible to study many aspects of immunity and patho-
genesis of the disease in humans. However, a recently
developed mouse model of Ebola virus infection, using a
mouse-adapted strain derived from the prototype (human)
Ebola Zaire 1976 isolate, may greatly facilitate the study of
several aspects of the disease (Bray et al., 1998).
The mouse-adapted virus produces disease in all strains
of mice tested, including BALB/c, C57/BL6, and outbred
strains (Bray et al., 1998). While there are many similarities
between the disease produced by the mouse-adapted virus in
mice and the disease in nonhuman primates and humans
(Gibb et al., 2001), a unique feature of this mouse-adapted
virus is the difference in outcome when adult mice are
infected via different routes. Mice infected by intraperito-
neal (ip) injection uniformly develop symptomatic infection
with rapid progression to death and 100% mortality (Bray et
al., 1998), even with a very low inoculum [1 plaque-
forming unit (PFU)]. However, the same virus, at doses as
high as 106 PFU per mouse, when injected subcutaneously
(sc), causes no illness or death in all the strains of mice
tested (Bray, 2001). The remarkable dichotomy in the
course of infection following virus entry by different routes
suggested that host factors, particularly differences in the
innate immune response, were likely to be involved (Bray,
2001).
The goal of this study was to examine kinetics of Ebola
virus growth and to identify potential mechanisms of patho-
genesis that determine different outcomes in mice infected
by two routes (sc and ip). With these data, we aim to better
understand the pathogenesis of acute Ebola virus infections
and to identify the correlates of immune protection in this
murine model that could guide the development of effective
Ebola vaccines. We show that the sc route of infection is
characterized by a slow rise in the virus load, apparently
allowing clearance, presumably by antiviral humoral and
cellular responses, whereas the rapid dissemination and
multiplication of virus after ip inoculation appears to cir-
cumvent or escape the same clearance mechanisms. Inflam-
matory responses, characterized by tumor necrosis factor
(TNF)- and monocyte chemotactic protein (MCP)-1 pro-
duction, appear early after ip infections, correlating with
increasing virus loads, whereas sc infection is associated
with early production of interferon (IFN)- and IFN-,
potent antiviral cytokines. The IFN- response in sc-in-
fected mice was associated with protection from rechallenge
as early as 48 h postinfection (pi). These data identify some
correlates of protection against Ebola virus in this model
and suggest a balance between protective immune responses
and replication of virus that might be manipulated to influ-
ence the outcome.
Results
Attenuated viral growth associated with sc infection when
compared with ip infections
Intraperitoneal infection of adult BALB/cj mice with 10
PFU (300 times the LD50) of the mouse-adapted Ebola
virus resulted in a uniformly fatal infection: 100% mortality
within 7 days (data not shown), whereas sc inoculation with
100 PFU resulted in no mortality. Furthermore, sc-infected
mice did not lose weight nor exhibit any overt signs of
illness (weight loss, ruffled fur, huddling, or inactivity), as
seen in mice infected ip. When mice surviving sc infection
were challenged by the ip route (106 PFU/mouse) 3 weeks
after the initial challenge, they again exhibited no signs of
illness, and 100% survived for the 21-day observation pe-
riod. As expected, the naı¨ve control group that received the
same dose of Ebola virus ip all died by day 7. Thus,
sc-infected mice acquire solid resistance against rechallenge
by a route (and dose) that normally results in fatal infection.
We examined viral antigen levels at different time points
during acute infection to determine if viral replication oc-
curred in sc-infected mice and to elucidate the relationship
between route of infection and viral growth. As seen in Fig.
1, viral antigen (AG) titers in liver, spleen, kidney, and
serum following a primary infection differed between ip-
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and sc-infected mice. After ip infection, virus AG titers rose
rapidly by day 4 and continued to rise until day 6, with death
occurring on days 6–7 postinfection, whereas sc infection
resulted in a delayed appearance of viral AGs in all tissues,
with peak titers that were 100- to 1000-fold lower than those
observed in ip-infected mice and returning to baseline by
day 15 (for organs) and day 21 for serum. A notable obser-
vation in the sc-infected mice was that virus AG first ap-
peared in the spleen (day 4 postinfection), then in the liver
and kidney on day 6, and much later in serum, where a peak
was reached on day 14 (Fig. 1).
As noted, mice infected sc demonstrated solid resistance
to ip rechallenge. Such resistance could be due to neutral-
ization of the virus at the point of entry (preventing any viral
growth), or to clearance of the virus after a period of
replication. To determine if virus replication did occur in the
immune mice, we measured virus AG titers in the serum and
tissues of mice challenged ip 3 weeks after sc infection.
These experiments revealed that very low titers of virus AG
were detectable on day 2 post-ip challenge in the serum,
liver, and spleen, but not in the kidney. Virus AG titers were
4–5 logs lower than in ip-infected mice and 1–2 logs lower
than in sc-infected mice (Fig. 1). In each tissue, viral AG
disappeared by day 6, indicating complete clearance of the
virus. Thus, in “immune” mice virus replication was not
completely prevented but rather was strongly attenuated and
the virus was rapidly cleared after rechallenge with a dose
that is normally lethal via the ip route.
To identify some correlates of protective immunity in
immune mice, we compared both innate and adaptive im-
mune responses in mice infected with Ebola virus via the sc
and ip routes. With regard to adaptive immunity, antibodies
have been proposed to play a protective role in several
animal models of Ebola virus infection (Gupta et al., 2001b;
Parren et al., 2002; Takada et al., 2003; Wilson et al., 2000;
Xu et al., 1998). Lethal (ip) infection with the mouse-
adapted Ebola virus was associated with a lack of detectable
anti-Ebola IgG up to the time death (data not shown). In
contrast, sc-infected mice had high titers of anti-Ebola IgG
on day 13 postinfection that remained essentially unchanged
up to the end of their 21-day observation period. Thus, in
experiments in which immune mice were rechallenged ip,
they had high anti-Ebola IgG titers at the time of rechal-
lenge on day 21 (Gupta et al., 2001b). Further, IgG titers
were boosted approximately fourfold by day 8 postchal-
lenge by the ip route in immune mice (data not shown).
These data are in agreement with previous studies that have
shown that anti-Ebola antibodies are able to protect against
fatal infection in some animal models (Gupta et al., 2001b;
Parren et al., 2002; Wilson et al., 2000). These results are
also consistent with clinical observations: human survivors
have high anti-Ebola IgG titers, whereas fatal cases have
low or undetectable titers of antibodies at the time of death
(Baize et al., 1999; Ksiazek et al., 1999a).
Nonlethal infection is associated with an early induction
of innate immune responses
Inhibition of innate antiviral mechanisms appears to play
an important role in viral replication and pathogenesis in
Ebola virus infections (Basler et al., 2000; Bray, 2001; Bray
et al., 2002; Harcourt et al., 1998, 1999). To ascertain the
role of innate immune responses in resistance to Ebola virus
infections in mice made immune by sc infection, we mea-
sured IFN- levels in tissues and sera of mice infected sc or
ip, and sc immune mice challenged ip (Fig. 2). We mea-
sured the levels of the mediator in target tissues (liver,
spleen, and serum) during two phases of infection: (i) the
early phase, immediately following exposure to the virus,
before detectable virus replication (the first 48 h of infec-
Fig. 1. Virus antigen kinetics in BALB/cj mice infected with a mouse-adapted Ebola virus ip, sc, or immune mice challenged ip. Viral antigen titers in the
liver, spleen, kidney, and serum of mice infected with Ebola virus ip (n  3 per time point; f), sc (n  3 per time point; Œ), sc-infected mice rechallenged
ip (n 3 per time point; ‚), or uninfected mice (n 2 per time point;). Symbols represent the mean viral antigen titer, measured by ELISA (see Materials
and methods) and error bars denote standard errors. Sera were serially fourfold diluted starting at a dilution of 1:50, and tissue homogenates (10% w/v in
PBS) were also fourfold diluted serially, starting at a dilution of 1:2. y-axes show AG titers, and x-axes show the day postinfection. The sensitivity threshold
of the assay ranged from 1:2 (for livers, spleens, and kidneys) to 1:40 (serum). All mice in an observation group infected ip died by day 7 postinfection.
Differences in antigen titers between ip-infected and sc-infected as well as immune rechallenged mice were statistically significant on days 5 and 6 (P 0.05;
ANOVA). Data are representative of two similar experiments.
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tion); and (ii) the late phase, when virus replication is easily
detected (days 2–18). In the studies of the early phase of
infection, inactivated virus produced a slight and transient
elevation of IFN- in tissues and sera in all the groups (ip,
sc, and immune rechallenged ip) returning to baseline
within 48 h (peak levels 200 pg/ml in all tissues). Mice
infected ip with live virus had low levels of IFN- (100
pg/ml) until day 5 when modest levels of the cytokine were
detected (959–1121 pg/ml average in the liver, spleen, and
serum; Fig 1). At this late stage of infection, virus antigen
levels were extremely high (titers  105). In striking con-
trast, tissue and serum IFN- levels in sc- infected mice
were significantly elevated as early as 2 days postinfection,
and even higher levels were found in the sc immune mice
upon rechallenge. Subcutaneously infected mice had a sus-
tained elevation of IFN- in all tissues from day 2 until day
10 (500–1250 pg/ml) and the levels then declined to base-
line by day 18 (Fig. 2). Immune mice had a similar rapid
rise in IFN- after ip challenge, but a more rapid decline,
reaching baseline values by day 10, a pattern that differed
considerably from that seen in mice infected ip (Fig. 2).
Thus, clearance of the virus correlated with an early innate
antiviral response, sustained throughout the period of viral
replication, as evidenced by detection of viral antigens
(Fig. 1).
The levels of the antiviral T cell derived cytokine IFN-
in tissues after Ebola virus infection were determined as a
surrogate for adaptive (cellular) immune responses. Inacti-
vated virus induced low levels of IFN- in ip and sc
“mock”-infected mice (100 pg/ml in homogenate in all
tissues). IFN- was detectable after 1 day in the spleen of
immune mice rechallenged with inactivated virus (272 
117 pg/ml of homogenate; Fig 2); however, this transient
increase declined by day 2 postinoculation and was signif-
icantly less than levels seen in mice infected with live virus.
Intraperitoneal infection with live virus resulted in undetect-
able levels of IFN- until day 5 postinfection, when modest
levels of the cytokine were detected in all tissues (Fig. 2). In
contrast, sc infection was associated with high levels of
IFN- on day 5 that were sustained up to day 10 postinfec-
tion, returning to baseline by day 18. In striking contrast,
immune mice rechallenged ip with Ebola virus had a rapid
IFN- response, within 48 h of infection, that was sustained
until day 8 postinfection, returning to baseline by about day
10, earlier than in sc-infected mice (Fig. 3). Thus, signifi-
cant adaptive cellular immune responses, represented by
IFN-, appeared only at late stages of infection in ip-in-
fected mice and during the phase of viral clearance in
sc-infected mice and in rechallenged mice.
Fig. 2. Nonlethal infection with Ebola virus is associated with early innate immune responses. BALB/cj mice were given a lethal ip infection (10 PFU/mouse),
a nonlethal sc infection (100 PFU/mouse) with Ebola virus, or an ip challenge (106 PFU/mouse) 3 weeks after an sc infection, as labeled. The levels of IFN-
(top graphs) and IFN- (bottom graphs) were determined in homogenates (10% w/v in PBS) of livers (f), spleens ( ), and serum () from mice sacrificed
at the indicated time points. Homogenates of livers from uninfected mice had 20 pg/ml of each cytokine. Data from separate experiments for the early time
points (0–2 days postinfection) and late time points (5–18 days postinfection) are combined. Each bar denotes the mean and standard error for three mice.
Each experiment was performed twice with similar results.
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Induction of inflammatory responses is associated with
lethal ip infection
Since monocytes and tissue macrophages are known to
be important targets of Ebola virus (Gibb et al., 2001;
Sanchez et al., 2001; Schnittler and Feldmann, 1999; Zaki
and Goldsmith, 1999), we examined the levels of represen-
tative monocyte-derived or macrophage-activating cyto-
kines (TNF-) and chemokine (MCP-1) involved in the
recruitment of macrophages and T cells into sites of infec-
tion. These mediators are induced by filovirus infection of
both human and murine macrophages (Gupta et al., 2001a;
Schnittler and Feldmann, 1999; Stroher et al., 2001) and are
suspected to play an important role in the pathogenesis of
Ebola virus in human and nonhuman primates (Hensley et
al., 2002; Hutchinson et al., 2001; Schnittler and Feldmann,
1998; Villinger et al., 1999). As with IFN- and IFN-, we
determined the patterns of production of these mediators in
target tissues during the early (days 0–2) and late (days
5–18) phases of infection.
We found very little sustained induction of these cyto-
kines by inactivated virus (data not shown). In the early
phase, ip injection of inactivated virus was associated with
a rise in TNF- levels in the liver (30  4 pg/ml), spleen
(118  10 pg/ml), and serum (79  9 pg/ml), whereas sc
inoculation resulted in a transient but minimal rise in TNF-
(100 pg/ml) in all tissues that returned to baseline by 48 h
postinfection (data not shown). MCP-1 responses to inacti-
vated virus were higher than the corresponding TNF-
responses, reaching peak levels of 205 and 266 pg/ml in the
homogenates of livers and spleen, respectively, at 12 h
postinfection only in immune ip rechallenged mice, but
returning to baseline levels by 2 days postinfection. After
live virus infection by both sc and ip routes, TNF- levels
were elevated in all tissues on day 5, with levels in ip-
infected mice (1980–2730 pg/ml) being significantly higher
than in sc-infected mice (780–1430 pg/ml; P  0.05; Fig.
3). Interestingly, TNF- levels were significantly lower in
immune-rechallenged mice, with a peak also at around day
5. TNF- levels correlated with the levels of virus AGs in
ip- and sc-infected mice, but in immune mice after rechal-
lenge, the levels were elevated well after day 2, the peak of
virus replication (Fig. 1). We used two approaches to de-
termine if TNF- plays a direct role in the pathogenesis of
fatal (ip) Ebola infections. First, survival of mice in which
TNF- and/or lymphotoxin (LT)- activity was blocked by
treatment with fusion proteins comprising the LT- receptor
(R) or TNF-R combined with an Fc molecule following
ip infection with Ebola virus was compared to that of
control mice and found to be identical (data not shown).
Second, mice genetically deficient in expression of TNF-R
(p75) were challenged ip with Ebola virus. These mice were
Fig. 3. Lethal Ebola virus infections are associated with secretion of inflammatory cytokines and chemokines. BALB/cj mice were infected in groups of 3
with sc (100 PFU of Ebola virus per mouse), ip (10 PFU per mouse), or immune mice were challenged ip (106 PFU per mouse) as labeled and the levels
of TNF- (top graphs) and MCP-1 (bottom graphs) were determined in homogenates of livers (f), spleens ( ), and serum (). Homogenates of livers from
uninfected mice had 20 pg/ml of TNF- and 40 pg/ml of MCP-1 (not shown). Separate experiments were done for the early time points (0–2 days
postinfection) and late time points (5–18 days postinfection), and the results of both are plotted together. Each bar denotes the mean and the error bar, the
standard error for a group. Data are representative of two experiments for each phase of infection.
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also found to have an identical survival pattern as that of
congenic controls (data not shown). From these preliminary
data, it appears that blockade of the high TNF- levels in
mice with fatal infections does not alter the course of in-
fection, suggesting that it is not the primary mediator of a
poor outcome in ip infections.
MCP-1 levels in tissues were elevated in a pattern similar
to TNF- in ip-infected mice with high levels on day 5
postinfection when viral AG levels were also markedly
elevated. In contrast, sc-infected mice had very low levels
of MCP-1 throughout the course of infection, and immune
mice rechallenged ip had an early, modest, and transient
elevation of MCP-1 that returned to baseline within 2 days
(Fig. 3). Taken together, these data confirm the notion that
secretion of these inflammatory cytokines and chemokines
accompanies the uncontrolled viral replication in macro-
phages that occurs in ip-infected mice. In sc-infected and
immune mice rechallenged ip, where viral replication is
modest or minimal, inflammation is correspondingly mild
or absent.
Innate resistance to rechallenge is dependent on virus
dose and interval after sc infection
Given that significant levels of IFN- were found in the
serum as early as 48 h after sc infection, we attempted to
determine whether this strong IFN response was involved in
protection of mice against an ip virus challenge. First, we
determined the interval after sc infection that was necessary
for the development of resistance. Mice infected sc with 106
PFU Ebola virus and then challenged ip with 10 PFU of
Ebola virus after 18 or 24 h had a mortality of 90 and 80%,
respectively (Fig. 4A). However, all the mice challenged at
48 h survived. Second, we determined the dose of sc-
inoculated virus required for development of resistance to
rechallenge at 48 h (Fig. 4B). The resistance to rechallenge
was found to be dependent on the dose of virus used in the
initial sc infection. All mice infected sc with 106 PFU
survived an ip rechallenge 48 h later, but mice given 105
PFU of virus sc had a 50% mortality and those that received
104 PFU virus sc had 90% mortality following ip re-
challenge 48 h later (Fig 4B). It should be noted that the
48 h interval after the sc infection, which appears to be
necessary for protection against ip rechallenge, coincides
with the induction of IFN- after sc infection (Fig 3) and is
too short an interval for the appearance of AG-specific
effector CD8 T cells. Thus, the early resistance, which
appears to be dependent on innate immunity, correlated
with the production of IFN-.
Discussion
The mouse model of Ebola virus infection has unique
features that make it possible to study susceptibility and
resistance to lethal infection in the same animal model and
to perform studies of the immunobiology of the virus and
testing of antiviral agents in ways that are not possible to do
in humans and nonhuman primates. Human infections are
rare, occurring in sporadic epidemics during which research
studies and testing of antiviral agents are difficult. Nonhu-
man primates, although excellent models for studies of
pathogenesis and therapy for Ebola virus, are expensive and
require specialized laboratories. A tremendous advantage of
the mouse model is the availability of a wide variety of
reagents and genetically altered mice that can be used to
study many aspects of the immune responses to the virus.
Indeed, studies using knockout mice for investigation of
pathogenesis and protective immunity against Ebola virus
are already under way in several laboratories (M. Bray and
M. Gupta, personal communication).
Previous studies with this mouse model of Ebola virus
infection have shown that the route of inoculation deter-
mines the outcome of infection (Bray, 2001; Gibb et al.,
2001). However, these studies did not report on the kinetics
of viral growth or on the type of immune response generated
by sc and ip infections. In this study, we have demonstrated
that viral loads are lower in sc- than in ip-infected mice and
that the virus is completely cleared within 14 days of infec-
tion. The complete recovery of sc-infected mice suggests
that the apparently slower replication and dissemination of
Fig. 4. Dependence of early resistance to Ebola virus in sc-infected mice on
innate immunity. (A) Groups of five BALB/cj mice were infected sc with
106 PFU Ebola virus per mouse and rechallenged ip (10 PFU of Ebola virus
per mouse) after varying intervals from 18–48 h as indicated by the key.
Rechallenged mice were observed for 14 days and survival or death was
recorded. (B) Groups of five BALB/cj mice were infected sc with different
doses of Ebola virus as indicated by the key and rechallenged ip with 10
PFU of Ebola virus per mouse after 48 h. Mice were observed for 14 days.
The y-axis represents percentage of mice surviving. EV: Ebola virus; Med:
medium alone.
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the virus may allow sufficient time or opportunity for the
host to generate or expand clearance mechanisms. Other
studies have implicated both humoral and cellular immunity
as effector mechanisms in the clearance of Ebola virus in
the mouse (Gupta et al., 2001b; Rao et al., 1999, 2002;
Wilson et al., 2001; Wilson and Hart, 2001). Our data
showing that in sc-infected mice, viral AG appears around
day 6 postinfection in the serum (Fig. 1) and, later on, in the
liver and spleen support the notion that viral replication
does occur but is both slower and lower in magnitude in sc
than in ip infections. Our antigen data in ip-challenged
immune mice (Fig. 1) indicate that, although the protection
in immune mice is solid, virus replication does occur ini-
tially, but rapid clearance is achieved without detectable
clinical symptoms.
The difference in the kinetics of TNF- and MCP-1
production in sc- and ip-infected mice is an important find-
ing in this study. These (and other) inflammatory mediators
have been proposed to play a role in the pathogenesis of
Ebola virus in humans (Leroy et al., 2000; Sanchez et al.,
2001; Villinger et al., 1999) and in the mouse model (Bray,
2001; Gibb et al., 2001; Gupta et al., 2001a; Peters and
LeDuc, 1999), and are likely involved in recruitment of
immune effector cells (macrophages, CD8 cells, NK cells)
to the sites of viral replication. TNF- may also participate
in the initiation of lymphocyte apoptosis, a prominent fea-
ture of Ebola virus infections in humans (Baize et al., 1999,
2000) that has also been demonstrated in nonhuman primate
models (Geisbert et al., 2000) and possibly in the massive
lymphocytolysis seen in mice (Gibb et al., 2001). In the case
of ip-infected mice, however, the pattern of early TNF-
secretion in serum and tissues, with a later, and modest
antiviral response (IFN- and -) after virus had replicated
to high titers (Figs. 1 and 3), suggests that a strong inflam-
matory response may portend a fatal outcome.
The role of IFN- and IFN- in protection as revealed by
our data appears to be complex. Although the levels of these
cytokines were elevated in the two groups that cleared the
virus (sc-infected and immune mice), the design of these
experiments did not allow us to distinguish between a caus-
ative role for these cytokines and an alternative role as
surrogates for some other viral clearance mechanism. How-
ever, data from other studies do ascribe a direct role to
IFN- in protection against Ebola virus in this murine
model (Bray, 2001; Bray et al., 2002). The first study by
Bray demonstrated that a nonlethal sc infection with the
mouse-adapted Ebola virus could be converted into a lethal
infection in IFN- receptor knockout mice and upon block-
ade of IFN- with antibodies (Bray, 2001). The author
concludes that induction of IFN- by the mouse-adapted
virus following sc infection may be a critical factor that
allowed the virus to be cleared in the murine host.
We and others have previously demonstrated that Ebola
virus inhibits the release of IFN- induced by double-
stranded RNA (Basler et al., 2000; Gupta et al., 2001a;
Harcourt et al., 1998, 1999). Here, we have shown that the
IFN- response to the virus differs depending on the route
of infection. Infection by the ip route results in a weak
IFN- response to Ebola virus early in infection. These
observations are consistent with earlier data in isolated
macrophages showing that Ebola virus inhibits IFN- re-
sponses to double-stranded RNA (Gupta et al., 2001a). In
contrast, sc infection results in an early and rapid production
of IFN- that is associated with protection from fatal dis-
ease. These interesting observations, taken together with the
data showing that the initial rise in IFN- levels in tissues
occurs after 24 h (Fig. 2), as well as the knockout experi-
ments described above (Bray, 2001), suggest that type I
IFN-mediated viral clearance plays a role in this early re-
sistance. The reason for this difference in IFN- responses
between the two routes of infection is not clear, but may be
related to the cells of the innate immune system that first
interact with the virus. The mechanisms involved in clear-
ance of Ebola virus have not been characterized to date but
accumulating evidence from this mouse model indicates
that CD8 T cells play a critical role (Wilson and Hart,
2001). Clearance mediated by CD8 T cells likely occurs at
a later stage of infection, only in animals that survive. Our
data and those reported from other models of viral infec-
tions suggest that IFN- may not only be important in the
early control of viral growth, but also has an important
regulatory role in generation of effector CD8 T cells re-
sponses later in infection, as has been proposed for other
viruses (Biron, 1998, 1999; Cousens et al., 1999).
An important difference between the sc and ip route of
infection that may explain differences in outcome is the
antigen-presenting cell populations involved in initiating the
immune response. Subcutaneous infection involves periph-
eral dendritic cell (DC) populations, such as Langerhans
cells or lymphoid interdigitating DC as the initial presenting
cells, whereas ip infection probably results in presentation
to T cells via peritoneal macrophages and macrophage-
derived DC. Differences in viral kinetics between the two
routes of infection may, therefore, be due to differences in
the antigen-presenting cell populations or to the cytokine
milieu associated with peripheral DC and peritoneal mac-
rophages (Banchereau et al., 2000; Pulendran et al., 2001).
It is tempting to speculate that differences in the ability of
Ebola virus or its proteins to inhibit early secretion of type
I interferons in macrophages and DC may play a role in the
differential clearance of the virus in sc and ip infections.
In this study, we explored an unusual feature of the
mouse model of Ebola virus infections, the differences in
outcome between two routes of infection, to identify poten-
tial mechanisms of pathogenesis and protective immunity
against Ebola virus. The observed delay and attenuation of
viral growth in sc-infected mice suggest a dynamic balance
between the virus and host clearance mechanisms leaning in
favor of the host in the sc route of infection. The mecha-
nisms of viral growth attenuation in sc infection are unclear,
but accumulating evidence suggests that they may operate
through the action of cellular antiviral defenses, such as type
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I IFNs. Exploitation of the mouse model to investigate these
antiviral defenses will undoubtedly advance our understand-
ing of the importance of innate and adaptive immune mech-
anisms in the development of protective immunity against
this virus.
Materials and methods
Virus, cells, and media
We used a mouse-adapted Ebola virus in our experi-
ments because pilot experiments demonstrated that a human
isolate of Ebola Zaire 1976 strain failed to produce infec-
tions in mice with doses as high as 106 PFU per mouse (data
not shown). The mouse-adapted strain of Ebola virus was
derived from Ebola Zaire 1976 by serial passage through
progressively older suckling mice, followed by plaque pu-
rification as described (Bray et al., 1998). For all our ex-
periments, we used a stock of the mouse-adapted strain after
one Vero E6 cell passage (titer 5  107 PFU/ml). Vero E6
cells (monkey kidney cell line, ATCC Vero C1008,
CRL1586) were propagated in modified Eagle’s medium
(EMEM), 2% fetal bovine serum, glutamine (2 mM, Life
Technologies, Gaithersburg, MD), streptomycin (100 g/
ml, Life Technologies), and penicillin (100 U/ml, Life
Technologies). In some experiments, aliquots of the viral
stocks were gamma-irradiated (5  106 rad in a Gammacell
220, Nordion, Canada) and used as inactivated controls.
Infectious material and animals were handled in a Biosafety
Level (BSL) 4 laboratory at the Centers for Disease Control
and Prevention (CDC), Atlanta, GA. All the samples
brought out from the BSL 4 laboratory were gamma-irra-
diated (5  106 rad) before further processing in BSL 2 and
3 facilities. This inactivation process has been previously
demonstrated not to affect the proteins measured in the
assays used (Mahanty et al., 1999).
Mice
Female BALB/cj mice (aged 6–8 weeks) were obtained
from commercial suppliers (Jackson Laboratory, Bar Har-
bor, ME and Harlan Sprague–Dawley, IN). All mice were
allowed to acclimate to the BSL4 laboratory conditions for
3–4 days before use in our experiments. Data shown are
representative of experiments repeated at least twice, using
groups of three mice. Animal use was in strict adherence to
the institutional guidelines for animal care at the CDC and
the U.S. Army Medical Research Institute for Infectious
Diseases.
Infection procedure
Lethal Ebola virus infections were produced by ip inoc-
ulation of 10 PFU of mouse-adapted Ebola virus (in 0.2 ml
of PBS), and nonlethal infections by 100 PFU of mouse-
adapted Ebola virus given sc. Subcutaneously infected im-
mune mice (referred to hereafter as immune mice) were
generated by infection with 100 PFU of live Ebola virus in
0.2 ml of PBS on the back below the neck (divided into two
inocula to avoid leakage of the inoculum from dense sc
tissue) as previously described (Bray et al., 1998). In ex-
periments focusing on adaptive immunity, mice were chal-
lenged by ip inoculation of 106 PFU of live Ebola virus 21
days after sc infection. In experiments focusing on innate
immunity, we rechallenged the mice ip with 106 PFU of
Ebola virus at various intervals ranging from 12 to 48 h post
sc infection with different doses (range 1–106 PFU/mouse).
After infection, ear-tagged mice were caged in groups of 3,
checked for survival daily, and weighed on alternate days
for at least 21 days.
Processing of tissues
For antigen and cytokine assays, 10% (w/v in PBS)
homogenates of gamma-irradiated tissues were prepared.
Cellular debris was pelleted by microcentrifugation and the
supernatant was used in assays as described below.
Quantitation of virus by antigen detection (ELISA) assay
Titers of Ebola viral antigens in sera and in homogenates
of organs were determined by a capture ELISA as described
(Ksiazek et al., 1992, 1999b). Briefly, 96-well plates (Fisher
Scientific, Atlanta, GA) were coated overnight at 4°C with
either a mixture of seven monoclonal mouse antibodies
(MAbs) raised against VP40, GP, and NP from Ebola Zaire
1976 and Ebola Sudan 1976 or normal mouse ascitic fluid
(for control wells). Tissue homogenates and serum samples
were serially diluted (fourfold) in 5% PBS-skim milk with
0.1% Tween 20 (blocking buffer), added to the wells in
duplicate, and incubated at 37°C for 1 h. Captured AG was
detected by polyclonal anti-Ebola Zaire serum produced in
rabbits and detected with a goat anti-rabbit HRP conjugate
(Kirkegaard and Perry, MD) and ABTS substrate (Kirkeg-
aard and Perry). The optical density (OD410) for each sam-
ple in control wells was subtracted from the OD of the
corresponding dilution of the same sample in wells coated
with anti-Ebola MAbs to derive a corrected OD. The highest
dilution of sample that resulted in a corrected OD of 0.1
corresponded to the viral AG titer of the sample. Viral AG
titers were found to have a log-linear relationship with viral
PFU counts (data not shown) for values  300 PFU. We
used viral AG titers to compare levels of virus in sera and
tissues.
Chemokine and cytokine assays
Sera and homogenates of livers and spleens were as-
sayed, after inactivation with gamma-irradiation (5  106
rad), using commercially available ELISA kits for the cy-
tokines TNF- (R&D Systems, Minneapolis, MN), IFN-
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(PBL, Inc., Princeton, NJ), IFN- (R&D), and MCP-1
(R&D) according to the manufacturers’ instructions. For the
purpose of comparison, values were expressed in pg/ml by
interpolation of sample OD values on standard curves gen-
erated with recombinant cytokines/chemokine.
Statistics
Comparisons of virus AG titers and cytokine levels in
sera and tissue between experimental groups were done
using the Student’s t-test on log-transformed data. Animal
weights and survival data were compared by ANOVA.
Differences between groups for categorical data were ana-
lyzed using the Fisher’s exact test. P -values of 0.05 were
used as the cutoff for statistical significance.
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